MAPT and Alzheimer disease: At the same time we found that progression to a clinical diagnosis of DLB or PD occurred only among participants who were LB+ at baseline, supporting the use of an α-syn SAA to identify preclinical LBD for early disease-modifying therapy trials in analogy to how Aβ and tau biomarkers are used today for preclinical AD trials.